申请人:MPG Max-Planck-Gesellschaft zur Förderung der
Wissenschaften e.V.
公开号:EP1854806A1
公开(公告)日:2007-11-14
The present invention relates to thioglycosides and stereoisomeric forms, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds, as well as pharmaceutical compositions containing at least one of these thioglycosides together with pharmaceutically acceptable carrier, excipient and/or diluents. Said thioglycosides have been identified as specific inhibitors of the sodium dependent glucose transporter 1 (SGLT1) and 2 (SGLT2), and are useful for the prophylaxis and/or treatment of hyperglycemia and hyperglycemia related diseases and conditions.
本发明涉及巯基糖苷类化合物和这些化合物的立体异构体、溶解物、水合物和/或药学上可接受的盐,以及含有至少一种巯基糖苷类化合物和药学上可接受的载体、赋形剂和/或稀释剂的药物组合物。上述硫代糖苷类化合物已被确定为钠依赖性葡萄糖转运体 1(SGLT1)和 2(SGLT2)的特异性抑制剂,可用于预防和/或治疗高血糖和高血糖相关疾病和病症。